Posts

Shionogi agrees to buy IntraBio for $2 billion

on
Shionogi agreed on October 5 to acquire Austin-based IntraBio for $2 billion in upfront cash, buying all of its outstanding shares. The deal is expected to close in November or December 2026, subject to regulatory approvals and other customary conditions. The main prize is Aqneursa (levacetylleucine), IntraBio’s treatment for neurological manifestations of Niemann-Pick disease type C. Recent reports say it has also received approval for ataxia-telangiectasia, giving Shionogi a foothold in two rare neurological disorders. Shionogi says the purchase will strengthen its rare-disease business and add IntraBio’s development expertise and pipeline. Reported programs include candidates for Pompe disease, Fragile X syndrome, and Jordan’s syndrome. The acquisition builds on Shionogi’s recent expansion into rare diseases, including its purchase of the ALS drug Radicava from Tanabe Pharma. Sources: www.shionogi.com · us · enShionogi Continues Rare Disease Expansion With Planned ... Sh...

BioSpace 40 Under 40 winners make their mark on biopharma

on

Shionogi to acquire IntraBio for $2 billion, expanding rare-disease portfolio

on

Three biotechs move toward IPOs as Lycia targets antibody degradation

on

Abbott wins FDA approval for patient-facing CardioMEMS features

on

Are physicians ready to embrace digital twins?

on

Rewind Therapeutics raises additional financing for oral remyelination program

on

Lilly expands Gate Bioscience deal with more than $870 million in potential payments

on

Candel Therapeutics to Present Two Posters at SITC 2026

on

RAG-18 shows early target engagement in a three-person DMD cohort

on

Vaxcyte shares surge after positive Phase 3 vaccine results

on

FDA extends review of Novo’s hemophilia A drug over factory remediation

on

Genentech licenses Alector’s preclinical Parkinson’s candidate for $100 million upfront

on